The FBXW7 antibody is a crucial tool in studying the FBXW7 protein, a tumor suppressor encoded by the *FBXW7* gene (F-box/WD repeat-containing protein 7). As a substrate-recognition component of the SCF (SKP1-CUL1-F-box protein) ubiquitin ligase complex, FBXW7 targets oncoproteins like c-MYC, Cyclin E, and NOTCH for ubiquitination and proteasomal degradation, thereby regulating cell cycle progression, genomic stability, and apoptosis. Mutations or dysregulation of FBXW7 are linked to various cancers, including colorectal, pancreatic, and hematologic malignancies, making it a focus in cancer research.
FBXW7 antibodies are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect FBXW7 expression levels, localization, and post-translational modifications in tissues or cell lines. These antibodies help identify loss-of-function mutations or reduced FBXW7 activity associated with poor prognosis. Specific clones or polyclonal variants may vary in reactivity across human, mouse, or rat samples, requiring validation for experimental contexts. Researchers also employ FBXW7 antibodies to explore its interactions with substrates or regulators, offering insights into therapeutic strategies targeting FBXW7-related pathways. Given its role in chemotherapy resistance and tumor suppression, FBXW7 remains a pivotal biomarker, with antibodies serving as essential reagents in both basic and translational oncology studies.